Despite the imminent patent expiry of many therapies,
the global immunology treatment market is set to expand, from $61.5 billion in
2015 to reach $74.2 billion in 2022, according to new research.
According to the company’s latest report, the
immunology treatment market’s Compound Annual Growth Rate (CAGR) will equal a
relatively stable 2.71%, due to practical and regulatory barriers to entry for
biosimilars that are not present for small molecule generics, and a moderately
strong late-stage pipeline.
According to Senior Analyst, says: “This market is a
lucrative area as up to 7% of western populations are thought to be affected by
chronic immunological disorders. Consequently, the pharmaceutical pipeline for
immunology is considerable, with 1,896 products currently in active development.
“While 85 of these are in Phase III of the process,
it must be acknowledged that 73% of these pipeline products are in early
developmental stages.”
Publisher’s study suggests there are a number of
prospective products expected to achieve strong annual revenues during the
forecast period, although these are not anticipated to achieve revenues
comparable to those generated by the current strongest-selling immunology
products.
Senior Analyst explains: “To date, the most
clinically and commercially effective drugs have been in a class of compounds
known as monoclonal Antibodies (mAbs), which includes blockbuster products such
as Humira (adalimumab) and Remicade (infliximab).
“APB-501, a biosimilar of Humira, which was the
best-selling drug of 2014 worldwide, is anticipated to generate annual revenues
of almost $1 billion by 2022, making it an exceptionally strong-performing
non-patented drug.”
The analyst adds that while the immunology
therapeutics market is a very commercially active area, with a number of
exceptionally high-selling products present, revenues for these key drugs are
expected to undergo a steady decline towards the end of the period.
Senior Analyst concludes: “Publisher believes that
revenues for immunology therapeutics will only significantly decline in the
long term, beyond the forecast period. This is due to the protective effect of
the practical and regulatory challenges in fielding biosimilar products, which
reduces the impact of patent expiries on biologics, compared with small molecules.”
Global Immunology Market to 2022 - Large pipeline and
competitive market to drive long-term market growth report provides analysis of
the immune-mediated inflammatory diseases treatment pipeline, stratified by
stage of development, molecule type and molecular target. It includes
information on the current clinical and commercial landscape, and the
composition of the immunology therapeutics space in terms of dominant molecule
types and targets, as well as highlighting key market players and their future
prospects.
This report was built using data and information
sourced from proprietary databases, primary and secondary research, and
in-house analysis conducted by Publisher’s team of industry experts.
For more information Visit at: http://mrr.cm/oVr
Find all Therapeutic
Report at: http://www.marketresearchreports.com/therapeutic
No comments:
Post a Comment
Note: only a member of this blog may post a comment.